Supernus Pharmaceuticals, Inc. (SUPN)Systematic Financial Management LP added to its stake +72K shares

376K

Shares reported · +72K vs prior quarter

0.45%

Disclosed portfolio weight

$19.4M

Reported value

Holdings as of

Mar 31, 2026

Filed

May 13, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Mar 3, 2026CongressDisclosed purchase of SUPN — reported range $1,001 - $15,000
2. Apr 1, 2026Company filing · Form 8-K · Material agreement, Acquisition or saleCompleted buying or selling a business or assets, and signed an important agreement“Completion of Acquisition or Disposition of Asset. The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this”
3. Apr 22, 2026Company filing · Form 8-K · ResultsReported its results
4. May 5, 2026Company filing · Form 8-K · ResultsReported its results

What came next

1. May 17, 2026Company filing · Form 8-K · New debtTook on new debt or obligations
2. Jul 22, 2026Company filing · Form 8-K · ResultsReported its results
3. Aug 1, 2026Company filing · Form 8-K · Material agreement, Executive changeChanged a top executive or board member, and signed an important agreement (and 1 more item)
4. Aug 3, 2026Company filing · Form 8-K · ResultsReported its results
5. Aug 31, 2026FDARecall: Trokendi XR, (topiramate) extended-release capsules, 50 mg, 30 Capsules, Rx only, Manufactured by: Catalent Pharma Solutions, Winchester, KY 40391 USA, Manufac…

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Supernus Pharmaceuticals, Inc.

For Supernus Pharmaceuticals, Inc., OQRO holds 2 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its SUPN page.

How this filing works

• SEC Form 13F

Other disclosures at Supernus Pharmaceuticals, Inc.

• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRJul 29, 2026
• SEC Form 13F-HRApr 28, 2026
• House Clerk periodic transaction reportApr 7, 2026
• SEC Form 13F-HRFeb 13, 2026
• SEC Form 13F-HRFeb 9, 2026

Everything OQRO holds on this company is on its SUPN page.